Phoenix PharmaLabs Strengthens its Position as a Developer of Next Generation Pain Pharmaceuticals with Acquisition of a Portfolio of NOP/Mu Agonist Compounds Full Article Beverly Jedynak2021-01-08T16:51:46+00:00 Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInTumblrPinterestVkEmail About the Author: Beverly Jedynak Related Posts https://investorplace.com/2021/01/7-equity-crowdfunding-offerings-to-buy-this-week-current/ https://investorplace.com/2021/01/7-equity-crowdfunding-offerings-to-buy-this-week-current/ January 28th, 2021 Phoenix PharmaLabs Announces new Offering with Netcapital Gallery Phoenix PharmaLabs Announces new Offering with Netcapital January 19th, 2021 Dr. Lawrence Toll Presents at NCATS-Sponsored Symposium Gallery Dr. Lawrence Toll Presents at NCATS-Sponsored Symposium February 9th, 2019